Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis
NCT07322003 is registered in ClinicalTrials.gov with Prilenia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis
- Lead sponsor
- Prilenia
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 1, 2026
- Completion date
- March 31, 2029
- Enrollment
- 500 (estimated)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.